This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Farkouh R, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C.Cost-effectiveness of rasagiline versus ropinirole extended release in delaying levodopa in the treatment of early Parkinson's disease in the United States. 13th International Congress of Parkinson's Disease and Movement Disorders: 376-377 abstr. Th-268, 7 Jun 2009. Available from: URL: http://www.movementdisorders.org
About this article
Cite this article
Economically, initiating treatment for Parkinson's disease with rasagiline dominates initiating treatment with ropinirole. Pharmacoecon. Outcomes News 581, 8 (2009). https://doi.org/10.2165/00151234-200905810-00024
- Public Health
- Lower Cost
- Health Outcome
- Markov Model